- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02505685
Dynamic PET CT as a Tool for Treatment Efficacy Monitoring in Lung Cancer
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
Background:
Lung cancer is a devastating disease in which the response for first line therapy is only 30%. Evaluating response is performed normally by a CT or PET-CT scans after 2-3 cycles of therapy, thus, lack of response is been evaluated only after the patient has been treated following significant amount of therapy, which is inefficient in 70% of cases.
Therefore, there is an urgent need to develop tools that might predict response to therapy during the early course of therapy; Most valuable will be before or after the first cycle of therapy. For that reason, the investigators aim in this study to evaluate the use of Dynamic PET-CT as a tool to assess disease response to anti-cancer therapy in Lung Cancer patients.
Objectives:
- To assess the feasibility of baseline Dynamic PET-CT as a tool for assessing response for anti-cancer therapy in Lung Cancer patients.
- To predict early response to treatment as soon as after 1 cycle of therapy by dynamic and static PET-CT.
- To correlate Dynamic PET-CT with survival/disease free survival
Method:
200 advanced lung cancer patients will be enrolled over 3 years in a single institute, single arm study at Rabin Medical Center, Beilinson Hospital.
Patients will be evaluated by a Dynamic PET-CT protocol: before initiation of therapy, 7-14 days after the first therapy cycle, 3 months after initiation of therapy and 6 months after the first therapy cycle. In addition, non-invasive biomarkers that are routinely measured including protein markers (CEA- Carcinoembryonic Antigen, CYFRA21- Cytokeratin 19 Fragment, NSE- Neuron Specific Enolase) will be assessed in this trial.
Disease response will be evaluated by Response Evaluation Criteria In Solid Tumors (RECIST criteria).
Additional PET-CT will not increase radiation dose significantly. The mean estimated radiation dose for a limited CT of the chest is about 14 mSv (i.e., 7mSv for limited diagnostic CT and FDG ([18F]-fluorodeoxyglucose), each). The dynamic stage will add radiation dose of about 0.3mSv. Of note, the significance of adding radiation dose is less of importance with regard to treatment of patients with aggressive cancer.
Undersøgelsestype
Tilmelding (Forventet)
Kontakter og lokationer
Studiesteder
-
-
-
Petach Tikva, Israel, 49100
- Rabin Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Age > 18 years.
- Lung cancer, stage 4
- Patients are planned to be treated by a systemic anti-cancer therapy.
- A define lesion for imaging.
- Able and willing to sign an informed consent form.
- First line therapy or at least 6 weeks after previous line of therapy
Exclusion Criteria:
- Pregnant or lactating women.
- Anti cancer therapy within the last 6 weeks before enrollment.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
---|
Lung cancer
People that were diagnosed with advanced lung cancer.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Compare baseline PET-CT with PET-CT after 7-14 days.
Tidsramme: 12 months
|
12 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Evaluate disease-free survival (DFS) in lung cancer by using dynamic PET-CT.
Tidsramme: 12 months
|
12 months
|
Evaluate overall survival rate (OS) in lung cancer by using dynamic PET-CT.
Tidsramme: 12 months
|
12 months
|
Measuring response to treatment by PET-CT.
Tidsramme: 12 months
|
12 months
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Nir Peled, MD PhD FCCP, Rabin Medical Center
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 0618-14-RMC
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Lungekræft
-
Mansoura UniversityRekrutteringOne Lung VentilationEgypten
-
Chinese Chronic Respiratory Disease Research NetworkRekruttering
-
Dokuz Eylul UniversityAfsluttetOne Lung VentilationKalkun
-
Seoul National University HospitalAfsluttet
-
Seoul National University HospitalAfsluttet
-
Yonsei UniversityAfsluttetOne Lung VentilationKorea, Republikken
-
Sichuan UniversityWest China HospitalMidlertidigt ikke tilgængeligOne Lung Ventilation
-
Joseph D. TobiasAfsluttetOne-lung Ventilation (OLV)Forenede Stater
-
University Health Network, TorontoAktiv, ikke rekrutterende
-
Papa Giovanni XXIII HospitalAfsluttetLungetransplantation | Ex Vivo Lung PerfusionItalien